iCAD (NASDAQ:ICAD) Price Target Raised to $15.00 at Craig Hallum
iCAD (NASDAQ:ICAD) had its price objective raised by Craig Hallum from $9.00 to $15.00 in a report published on Thursday morning, The Fly reports. Craig Hallum currently has a buy rating on the technology company’s stock.
Several other brokerages also recently issued reports on ICAD. Dougherty & Co assumed coverage on iCAD in a report on Friday, December 20th. They set a buy rating and a $10.00 price target for the company. Lake Street Capital assumed coverage on iCAD in a report on Thursday, January 9th. They set a buy rating and a $14.00 target price for the company. Finally, JMP Securities assumed coverage on iCAD in a report on Wednesday, February 5th. They set an outperform rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $13.50.
iCAD stock traded up $0.22 during mid-day trading on Thursday, hitting $11.98. 525,000 shares of the company’s stock traded hands, compared to its average volume of 224,138. The firm has a 50 day simple moving average of $8.77 and a two-hundred day simple moving average of $7.34. iCAD has a fifty-two week low of $4.05 and a fifty-two week high of $12.32. The stock has a market cap of $226.29 million, a price-to-earnings ratio of -15.56 and a beta of 1.09. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.76 and a quick ratio of 1.62.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Featured Story: S&P 500 Index
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.